Personal del departament

Josep B. Cladera Cerdà
  • Biografia
  • In the last ten years my research activity has been dedicated to two research lines: (1) My main research line, the characterization of amyloid peptides and proteins related to conformational diseases and of dendrimers as antiamyloidogenic agents; and (2) the recombinant expression and characterization of membrane transporters.
    The studies on amyloid peptides related to conformational diseases have been carried out in close collaboration with Núria Benseny, currently a postdoctoral researcher at ALBA Synchrotron, and three other important collaborations: (1) Prof. I. Ferrer’s laboratory at IDIBELL (Barcelona); (2) Profs. M. Bryszewska and B. Klajnert, at the University of Lodz (Poland); (3) Dr. Dietmar Appelhans, at the Institute of Polymer Research in Dresden (Germany).
    A recent review containing some important results from these collaborations has been published in Progress in Polymer Science (Magnani et al. 2017, Prog Polym Sci 64:23-51), entitled ‘Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches’.
    Moreover, I have recently collaborated with Prof. Gunnar Gouras from the Unversity of Lund (Sweden) in a study in which synchrotron-based infrared imaginghas been used for identification of amyloid pre-plaques in a transgenic mouse model of Alzheimer, and which has been published in Nature Communications (Nat Commun 2017, 8:14726).
    The research on the molecular characterization of the amyloid aggregates related to the onset and development of the so called conformational diseases, such as Alzheimer’s and prion diseases, has been focused on the characterization of the amyloid oligomeric (non fibrillar) toxic species and on the effects of the amyloid peptides on model (liposome) biological membranes. In parallel, the research has been focused in using dendrimers as potential antiamyloidogenic agents. Looking into this problem implied the establishment of a consortium that resulted in a COST Action on the Biomedical Applications of Dendrimers (TD0802, 2008-2013), chaired by Dr. Barbara Klajnert and in which I was the coordinator of the Working Group 4, dedicated to the investigation of potential biomedical applications of dendrimers. It was within this frame that I started to work with Dr. Dietmar Appelhans’ group in Dresden, a specialist in glycodendrimers. First, we described that glycodendrimers are biocompatible and are able to block amyloid toxicity in neuroblastoma cell cultures. After that, and in collaboration with Prof. Isidre Ferrer from IDIBELL in Barcelona, we showed that glycodendrimers are biocompatible and more importantly, they can cross the BBB when administered intranasaly in a murine model. The glycodendrimers design has been improved and at present, the group has preliminary results showing that glycodendrimers decorated with histidine cause a memory recovery in transgenic model.
    In the last three years, my group has specialized as well in synchrotron-based micro-FTIR and X-ray fluorescence spectroscopies, which allow for the in situ characterization of amyloid deposits (in brain sections) and of characteristic hallmarks of the pathology such as oxidative stress and metal ion levels variations.

  • Grups de recerca
  • Biologia Estructural de la Malaltia d’Alzheimer. Estudis Biofísics.
  • Altres informacions
  • Researcher ID: E-6737-2010



2022 Universitat Autònoma de Barcelona